▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Genexine’s diabetes treatment wins IND approval in Germany

  • PUBLISHED :January 18, 2017 - 17:04
  • UPDATED :January 18, 2017 - 17:47
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] South Korea’s biotechnology company Genexine said on Jan. 18 that its plan to conduct phase 1 clinical trials for its GX-G6, long-acting glucagon-like peptide-1 has been cleared by Germany’s medical regulator.

The Federal Institute for Drugs and Medical Devices approved the company’s investigational new drug application to access GX-G6 in the treatment of Type 2 diabetes. 




Related:
Can Genexine break into global long-acting growth hormone market?
Genexine to begin clinical trials of HPV-induced cervical cancer drug



GX-G6 is long-acting GLP-1 for Type 2 diabetes targeting both weekly and twice-monthly regimen compared to conventional daily therapeutics.

The phase 1 clinical trials are scheduled to begin in the first half of 2017 with plans to enroll up to 48 healthy volunteers in Germany.

According to the GlobalData report, the global Type 2 diabetes pharmaceutical market in 2015 was US$31.2 billion, including both branded and generic drugs.

The sales of GLP-1 receptor agonists therapeutics was US$3.8 billion, taking 9 percent of the overall Type 2 diabetes market in 2016.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS